Skip to main content
Quantum Genomics logo

Quantum Genomics — Investor Relations & Filings

Ticker · ALQGC ISIN · FR0011648971 LEI · 969500TFCD8K9RPM9K97 PA Manufacturing
Open in API
Filings indexed 341 across all filing types
Latest filing 2019-04-26 Regulatory Filings
Country FR France
Listing PA ALQGC

About Quantum Genomics

https://quantum-genomics.com/

Quantum Genomics is a biopharmaceutical company focused on developing a new class of medications for cardiovascular diseases with high unmet medical needs, such as difficult-to-treat or resistant hypertension and heart failure. The company's core research is based on a breakthrough therapeutic approach involving the inhibition of Brain Aminopeptidase A (BAPA). Its lead drug candidate, firibastat, is a first-in-class BAPA inhibitor designed to offer a novel treatment mechanism for managing these conditions.

Recent filings

Filing Released Lang Actions
Quantum Genomics annonce la publication des résultats de son étude de Phase IIb NEW-HOPE dans l'hypertension artérielle dans le journal Circulation
Regulatory Filings Classification · 96% confidence The document is an announcement by Quantum Genomics stating that the results of their Phase IIb NEW-HOPE study have been published in the journal *Circulation*. It details the title of the article, confirms the efficacy data, and mentions the context of the publication (AHA scientific sessions). This is not a full financial report (like 10-K or IR), nor is it a standard earnings release (ER). It is an announcement about the publication of scientific/clinical data, which often falls under general regulatory announcements or investor relations updates. Given the options, this is a specific type of announcement related to company progress, but it doesn't fit perfectly into the financial reporting codes (10-K, IR, ER). Since it is an announcement about a significant event (publication of study results), and it is not a formal regulatory filing like a Director's Dealing or Major Shareholding, the most appropriate general category for non-standard, important corporate news that isn't a financial report or management change is Regulatory Filings (RNS), as it serves as a general announcement mechanism for material, non-financial news. However, if we consider the context of investor communication, it is an announcement of a key development. Since there is no specific code for 'Clinical Trial Result Announcement', RNS is the best fit as a general regulatory/material disclosure, or potentially LTR if the focus was on legal/regulatory action, but here it's positive scientific news. Given the options, RNS is the most suitable fallback for material, non-financial disclosures.
2019-04-26 French
Quantum Genomics Receives First Regulatory and Ethics Approvals to Initiate Phase IIb QUORUM Study of Firibastat in Heart Failure
Regulatory Filings Classification · 100% confidence The document is a press release from Quantum Genomics announcing that they have received the first regulatory and ethics approvals (specifically from ANSM in France) to initiate their Phase IIb QUORUM study for firibastat in heart failure. This type of announcement, detailing clinical trial progress, regulatory milestones, and providing background context on the disease and the company, is characteristic of general corporate news releases intended for investors and the public. It is not a formal regulatory filing like a 10-K, an earnings release (ER), a detailed interim report (IR), or a presentation (IP). Since it is a specific announcement about clinical/regulatory progress that doesn't fit the other specific categories (like DIRS, DIV, CAP, etc.), the most appropriate classification is the general 'Regulatory Filings' fallback category (RNS), as it is a formal announcement of a regulatory event, although it is primarily a press release. Given the options, RNS serves as the best fit for general corporate news/announcements that aren't strictly financial reports or specific insider/dividend actions.
2019-04-17 English
Quantum Genomics reçoit les premiers avis favorables des comités d'éthique et des autorités réglementaires pour lancer l'étude de Phase IIb QUORUM sur le firibastat dans l'insuffisance cardiaque
Regulatory Filings Classification · 95% confidence The document is a press release from Quantum Genomics announcing that they have received favorable opinions from ethics committees and regulatory authorities (specifically mentioning the ANSM in France) to launch a Phase IIb clinical study (QUORUM) for their drug firibastat in heart failure treatment. This type of announcement, detailing clinical trial progress, regulatory milestones, and scientific updates, is characteristic of corporate communications aimed at investors and the public. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a full interim report (IR). Since it is a specific announcement about a corporate event (clinical trial initiation approval) that doesn't fit perfectly into the other specific categories (like M&A, Dividend, or Management Change), it falls best under the general 'Regulatory Filings' (RNS) category, which serves as a broad category for significant, non-standard corporate news releases, or potentially 'Capital/Financing Update' (CAP) if the trial launch was tied to specific funding, but the focus here is purely operational/clinical progress. Given the options, RNS is the most appropriate catch-all for a significant operational press release that isn't a financial report or a specific transaction notice. The document length (7901 chars) is substantial enough that it is the report itself, not just an announcement of a report (ruling out RPA).
2019-04-17 French
Information relating to the total number of voting rights forming the share capital
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document explicitly details the 'Total number of shares forming the share capital' and 'Total number of voting rights' as of a specific date (03/31/2019), referencing French commercial code and AMF regulations. This type of mandatory disclosure regarding the total voting structure is typically associated with regulatory filings concerning share capital or voting rights announcements. Among the provided codes, 'Declaration of Voting Results & Voting Rights Announcements' (DVA) is the most specific fit for a formal declaration of the total number of voting rights, even if it's not the result of a specific vote, but rather a periodic update on the capital structure relevant to voting rights. It is not a full financial report (10-K, IR) or a management change announcement (MANG). Given the focus on voting rights structure, DVA is the best classification.
2019-04-15 English
Information relative au nombre total de droits de vote et d'actions composant le capital
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Information relative au nombre total de droits de vote et d'actions composant le capital" (Information relative to the total number of voting rights and shares comprising the capital) and explicitly references Article L. 233-8-II of the French Commercial Code and Article 223-16 of the AMF General Regulation. It provides a table detailing the number of shares and total voting rights as of a specific date (31/03/2019). This type of mandatory disclosure regarding the total share capital and voting rights is a specific regulatory filing in France, often related to changes in capital structure or required periodic updates. While it touches upon capital structure, it is not a general financing announcement (CAP) or a share issue announcement (SHA) in the typical sense, but rather a mandatory disclosure of the current capital base. In the context of the provided definitions, this specific type of capital structure disclosure, which is often filed periodically or upon request by regulators (like the AMF), fits best under the general regulatory filing category, 'RNS' (Regulatory Filings), as it doesn't align perfectly with the more specific financial report types (10-K, IR, ER) or corporate action types (SHA, POS). Given the regulatory nature and the specific French legal references, RNS is the most appropriate fallback for this mandatory disclosure.
2019-04-15 French
Quantum Genomics Reports Full-Year 2018 Financial Results
Earnings Release Classification · 99% confidence The document is explicitly titled "Quantum Genomics Reports Full-Year 2018 Financial Results." It contains detailed financial tables (Income, Operating income, Net income) for the fiscal year ending December 31, 2018, and discusses R&D progress and cash position for the full year. This content aligns perfectly with the definition of an Annual Report (10-K), which covers company activity and full financial performance for the year. Although it is a press release summarizing the results, the depth of the financial data and the reference to the 'annual financial report' being available strongly suggest this document serves as the primary disclosure of the annual results, fitting the '10-K' category better than a simple 'ER' (Earnings Release) which is usually quarterly and less comprehensive, or 'RPA' which is just an announcement of a report's availability. Given the context of a comprehensive annual financial summary, 10-K is the most appropriate classification. FY 2018
2019-03-28 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.